why choose us

300×250 Ad Slot

Research Article: Transfusion practices, thresholds, and complications in pediatric oncology patients: a single-center prospective longitudinal observational study

Date Published: 2026-09-30

Abstract:
This study aimed to evaluate the frequency, indications, pre-transfusion threshold values, associated risk factors, and complications of blood product transfusions in pediatric oncology patients to contribute to the development of evidence-based, standardized transfusion strategies. This single-center, prospective observational study included 41 pediatric oncology patients aged 1 to 18 years who received red blood cell (RBC), platelet, or fresh frozen plasma (FFP) transfusions between June 2023 and June 2024. Patients were followed throughout their treatment and for six months after their final transfusion. Among 404 transfusions (215 RBC, 183 platelet, 6 FFP), the mean number per patient was 9.78?±?9.2. Pre-transfusion platelet thresholds were significantly higher in the leukemia/lymphoma group than in the solid tumor group (23,892?±?11,773/mm 3 vs. 16,669?±?11,921/mm 3 ; p < 0.001), while RBC hemoglobin thresholds were similar (7.4?±?0.6 vs. 7.3?±?0.8 g/dL; p =?0.67). Advanced-stage disease ( p =?0.04) and relapsed or refractory disease ( p =?0.026) were associated with increased RBC transfusion requirements. Acute reactions occurred in 12.4% of transfusions, most (84%) being febrile nonhemolytic reactions. Premedication did not prevent reactions ( p =?0.6). During long-term follow-up, serum ferritin exceeded 1000 ng/mL in 45.7% of patients. Transfusion management varies by diagnosis, with platelet thresholds in hematologic malignancies maintained higher than literature recommended. Advanced-stage and relapsed or refractory disease increase the transfusion burden. The high incidence of acute reactions and iron overload underscores the need for transfusion safety, long-term monitoring, and standardized, evidence-based transfusion strategies in pediatric oncology.

Introduction:
Diagnostic and therapeutic advances over the past three decades have significantly improved survival rates for childhood cancers ( 1 ). Currently, long-term survival rates for many pediatric malignancies exceed 80%. This success is due not only to effective antineoplastic therapies but also to comprehensive supportive care, including infection control, nutritional support, and transfusion practices ( 2 ). Intensive chemotherapy protocols, hematopoietic stem cell transplantation procedures, and disease-related bone…

Read more

300×250 Ad Slot